The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NNVC | +2.68% | -60.77% | -17.05% | -90% |
| S&P | +16.9% | +95.99% | +14.39% | +464% |
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
Inovio Pharmaceuticals, Novavax, and Nanoviricides are developing treatments for the deadly MERS virus. Here’s what you need to know.
These five stocks posted double-digit percentage declines.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.16M | 15.5% |
| Market Cap | $22.50M | 10.7% |
| Market Cap / Employee | $3.21M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$2.10M | 11.0% |
| EBITDA | -$1.95M | 11.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.56M | -67.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -87.47% | -31.7% |
| Return On Invested Capital | -51.31% | 1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.71M | -8.4% |
| Operating Free Cash Flow | -$1.70M | -14.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.72 | 1.99 | 1.76 | 2.55 | 33.53% |
| Price to Tangible Book Value | 1.77 | 2.06 | 1.82 | 2.64 | 34.27% |
| Enterprise Value to EBITDA | -5.62 | -9.06 | -7.88 | -11.03 | 50.08% |
| Return on Equity | -81.9% | -82.0% | -99.8% | -99.7% | 58.33% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
